CAS: 226256-56-0; (R)-N-(1-(Naphthalen-1-yl)Ethyl)-3-(3-(Trifluoromethyl)Phenyl)Propan-1-Amine

该化合物是一种合成化合物,主要用于治疗透析慢性肾病患者的二次超常固醇,治疗对对硫酸固醇肿瘤患者的超高血压,它作为一种碳化剂发挥作用,这意味着它能提高钙感应器对对对显性细胞的敏感度,从而减少类固醇的分泌和降低血清钙含量.胆碱酯的化学配方是C22H28N2O2S,其分子重量约为372.54克/摩尔.胆碱酯一般是口服的,以其生物利用率相对较高而著称.其致癌细胞细胞病表明,其肝脏中广泛代谢,主要是通过细胞色素P450酶.常见副作用可能包括恶心,呕吐和低血清.与任何药物一样,对于病人来说,对于潜在不利影响和确保与甲醇相关的高压病候调节来说,它对于监测病人具有关键作用,对于确保与甲状腺激素相关的高血压管理具有关键作用.

结构式图片

欧盟法规

C&L通报

上下游产品

α-Methyl-N-[3-[3-(Trifluoromethyl)Phenyl]Propyl]-1-Naphthalenemethanamine 1025064-33-8
(R)-N-(1-(萘-1-基)乙基)-3-(3-(三氟甲基)苯基)丙酰胺 (R)-N-(1-(Naphthalen-1-yl)Ethyl)-3-(3-(Trifluoromethyl)Phenyl)Propanamide 1005450-55-4
(R)-3-(1-(1-Naphthyl)Ethylamino)-1-(3-(Trifluoromethyl)Phenyl)Propan-1-One
(R)-(1-Naphthalen-1-Yl-Ethyl)-[3-(3-Trifluoromethyl-Phenyl)-Allyl]-Amine
西那卡塞杂质4 (2E)-N-[(1R)-1-(1-Naphthyl)Ethyl]-3-[3-(Trifluoromethyl)Phenyl]Prop-2-En-1-Amine 955373-56-5
3-(3-Trifluoromethyl-Phenyl)-Propynoic Acid ((R)-1-Naphthalen-1-Yl-Ethyl)-Amide 1095393-72-8
(E)-N-((R)-1-萘-1-基-乙基)-3-(3-三氟甲基-苯基)-丙烯酰胺 (E)-N-((R)-1-Naphthalen-1-Yl-Ethyl)-3-(3-Trifluoromethyl-Phenyl)-Acrylamide 1095393-66-0
3-Chloro-N-[(1R)-1-(Naphthalen-1-yl)Ethyl ]Prop-2-En-1-Amine 1279582-34-1 N-((R)-1-Naphthalen-1-Yl-Ethyl)-Acrylamide 1095393-70-6 (R)-N-[3-[3-(Trifluoromethyl)Phenyl]-2-Propenylimino]-N-[1-(1-Naphthyl)Ethylamine] 1201910-95-3

合成工艺路线路线简述

  • 合成目标产物 Cinacalcet 主要起始原料 Benzeneacetic Acid, α-Hydroxy-, (αr)-, Compd. With (αr)-α-Methyl-1-Naphthalenemethanamine (1:1) And Methanesulfonic Acid 3-(3-Trifluoromethylphenyl)Propyl Ester
  • (文献来源)合成步骤主要原料 Benzeneacetic Acid, α-Hydroxy-, (αr)-, Compd. With (αr)-α-Methyl-1-Naphthalenemethanamine (1:1) 和 Methanesulfonic Acid 3-(3-Trifluoromethylphenyl)Propyl Ester
(R)-(1-Naphthalen-1-Yl-Ethyl)-[3-(3-Trifluoromethyl-Phenyl)-Allyl]-Amine置于5%-Palladium/activated Carbon 氢气体系中,用 甲苯 用作溶剂,10.0~30.0 °C,152.0 Kpa 条件下,以79.4%的收率获得西那卡塞
参考文献: A Process For The Synthesis Of Cinacalcet Hydrochloride[fr] Procédé Pour La Synthèse De Chlorhydrate De Cinacalcet
标题: A Process For The Synthesis Of Cinacalcet Hydrochloride[fr] Procédé Pour La Synthèse De Chlorhydrate De Cinacalcet
摘要:描述了一种用于制备盐酸西那卡塞的过程,包括以下步骤:A)将(R)-(+)-1-(1-萘基)乙胺(II)与3-[3-(三氟甲基)苯基]丙烯醛(III)反应,得到非隔离的中间体(R)-N-[3-[3-(三氟甲基)苯基]-2-丙烯基亚胺-N-[1-(1-萘基)乙胺(Iv);B)用顺序加入的方式还原非隔离的中间体(R)-N-[3-[3-(三氟甲基)苯基]-2-丙烯基亚胺-N-[1-(1-萘基)乙胺(Iv),包括:-氢硼酸钠,甲醇和碱的溶液,-草酸和-碱,以获得(R)-N-[3-[3-(三氟甲基)苯基]-2-丙烯基]-1-(1-萘基)乙胺(V),在加入草酸后通过沉淀化合物(V)的草酸盐而得到;C)氢化(R)-N-[3-[3-(三氟甲基)苯基]-2-丙烯基]-1-(1-萘基)乙胺(V),从而获得(R)-N-(3-(3-(三氟甲基)苯基)丙基)-1-(1-萘基)乙胺西那卡塞碱(Vi),在乙酸乙酯中重新提取;D)用盐酸处理乙酸乙酯中的西那卡塞碱(Vi)溶液,得到盐酸西那卡塞(I).

海关参考信息

专利信息


专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:US-8614354-B2
优先权日:2008-06-18
标题 :Process for the synthesis of cinacalcet hydrochloride
发明人:FERRARI MASSIMO; GHEZZI MARCELLO; BONALDI MATTEO
权利人:FERRARI MASSIMO; GHEZZI MARCELLO; BONALDI MATTEO; ERREGIERRE SPA
摘要:There is described a process for the preparation of cinacalcet hydrochloride (I) which includes the steps of: a) reacting (R)-(+)-1-(1-naphthyl)ethylamine (II) with 3-[3-(trifluoromethyl)phenyl]propenaldehyde (III) to afford the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[1-(1-naphthyl)ethylamine (IV); b) reducing the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[-1-(1-naphthyl)ethylamine (IV) with a sequential addition of:—a solution of sodium borohydride, methanol and a base,—oxalic acid and—a base to obtain (R)—N-[3-[3-(tifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) by passing through the precipitation of the oxalate salt of compound (V) after the addition of oxalic acid; c) hydrogenating (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) thus obtaining (R)—N-(3-(3-(trifluoromethyl)phenyl]propyl]-1-(1-naphthyl)ethylamine cinacalcet base (VI), which is retaken in ethyl acetate; and d) treating the solution of cinacalcet base (VI) in ethyl acetate with hydrochloric acid to afford cinacalcet hydrochloride (I).

专利号:WO-2025099741-A1
优先权日:2023-11-07
标题:Process for the preparation of nitrosamine free cinacalcet and salts thereof
发明人:BIRARI DILIP RAMDAS; SHINDE GORAKSHANATH BALASAHEB; TELDHUNE Ashish Pramod
权利人:MEGAFINE PHARMA P LTD; BIRARI DILIP RAMDAS; SHINDE GORAKSHANATH BALASAHEB; TELDHUNE Ashish Pramod
摘要:The present invention relates to a process for preparation of nitrosamine free Cinacalcet (1) and salts thereof. Wherein, Cinacalcet (1) and its salts is substantially free of nitrosamine impurities by using of an antioxidant in the process for synthesis of Cinacalcet (1) and its pharmaceutically acceptable salts.

专利号:US-2010267988-A1
优先权日:2006-06-08
标 题:Processes for preparing intermediate compounds useful for the preparation of cinacalcet
发明人:SZEKERES TIBOR; REPASI JOZSEF; SZABO ANDRAS; MANGION BERNARDINO
权利人:MEDICHEM SA
摘要:The invention relates, in general, to an improved process for preparing compounds (e.g., 3-(3-trifluoromethylphenyl)propanal (Compound III, below)), which are key intermediates for the synthesis of cinacalcet, its salts and/or solvates thereof, as well as the use of such compounds prepared by such process for the preparation of cinacalcet and/or its salts or solvates.

专利号:US-10865163-B2
优先权日:2017-12-20
标题:Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds
发明人:YOUNG MICHAEL C; KAPOOR MOHIT
权利人:UNIV TOLEDO
摘要:Methods of synthesizing compounds using CO 2 as a directing group for C—H functionalization, and compounds made thereby, are described.

专利号:EP-1990333-A1
优先权日:2007-05-11
标题 :Process for the preparation of cinacalcet hydrochloride
权利人:SANDOZ AG
摘要:The present invention relates to a process for the preparation of cinacalcet hydrochloride which is industrially feasible and commercially viable. The synthesis of cinacalcet hydrochloride is carried out by the condensation of 3-trifluromethylphenyl propionic acid with R-(+)-1-(lnaphthyl)ethylamine.
北京迈索化学技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huafenginfo.com
企业联系电话:010-57862036,65405760👤
📞北京迈索化学技术有限公司 ⚠️参考联系方式
联系人:崔先生
电话:010-57862036,65405760
手机:13366977697
传真:010-57862181
邮箱:sales@mesochem.com
通信地址: 北京市亦庄经济技术开发区荣华中路力宝广场9座23层
邮编: 100176
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:北京市亦庄经济技术开发区荣华中路力宝广场9座23层
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
湖北猫尔沃生物医药有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.marvel-bio.com
企业联系电话:15387162023👤
📞湖北猫尔沃生物医药有限公司 ⚠️参考联系方式
联系人:宋经理
电话:15387162023
手机:15387162023
传真:027-877288767
邮箱:1824363398@qq.com
通信地址: 湖北省高新技术开发区关山大道
邮编: 430070
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖北省高新技术开发区关山大道
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
常州瑞明药业股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.ruimingpharm.com
企业联系电话:0519-86920910;18261172629;18118380910👤
📞常州瑞明药业股份有限公司 ⚠️参考联系方式
联系人:夏文华
电话:0519-86920910;18261172629;18118380910
手机:18261172629;18118380910
传真:0519-86920912
邮箱:swm@ruimingpharm.com
通信地址: 江苏省常州市龙江北路1558号
邮编: 213127
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:江苏省常州市龙江北路1558号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州沃德凯化工原料有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.chinaworldchem.com
企业联系电话:0576-85301198👤
📞台州沃德凯化工原料有限公司 ⚠️参考联系方式
联系人:张先生
电话:0576-85301198
手机:13736201658
传真:0576-85308398
邮箱:sales@chinaworldchem.com
通信地址: 浙江省临海市巾山东路望江银座2单元1001
邮编: 317000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省临海市巾山东路望江银座2单元1001
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142. 35(9):1679-1697. doi: 10.1007/s00467-020-04516-4. Epub 2020 May 4.
3: Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. 23(3):485-501. doi: 10.1007/s11154-021-09694-6. Epub 2022 Jan 18. 6(6):587-92.
42:1-90. doi: 10.1016/bs.podrm.2017.02.001. Epub 2017 Apr 3. 28(6):594-603. doi: 10.1111/sdi.12413. Epub 2015 Aug 12. 13 Suppl

合成参考文献


参考文献:10.1155/2011/251410
摘要:MacKenzie-Feder J, Sirrs S, Anderson D, Sharif J, Khan A. Primary Hyperparathyroidism: An Overview. International Journal of Endocrinology. 2011;2011():1–8. doi: 10.1155/2011/251410.
参考文献:10.4061/2011/982854
摘要:New N, Mohandas J, John GT, Ratanjee S, Healy H, Francis L, Ranganathan D. Calcific Uremic Arteriolopathy in Peritoneal Dialysis Populations. International Journal of Nephrology. 2011;2011():1–9. doi: 10.4061/2011/982854.
参考文献:10.4061/2011/906832
摘要:Messa P, Cafforio C, Alfieri C. Clinical Impact of Hypercalcemia in Kidney Transplant. International Journal of Nephrology. 2011;2011():1–9. doi: 10.4061/2011/906832.
参考文献:10.5414/cn106640
摘要:Battistella M, Richardson RM, Bargman JM, Chan CT. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease. Clin Nephrol. 2011 Aug;76(2):99–103. doi: 10.5414/cn106640.
参考文献:10.1016/j.endonu.2011.05.007
摘要:Prieto Tenreiro AM, García López JM, García Vázquez M, Puñal Rodríguez JA, Casanueva FF. [The value of selective parathyroid venous sampling for localizing occult parathyroid adenomas]. Endocrinol Nutr. 2012 Jan;59(1):73–6. doi: 10.1016/j.endonu.2011.05.007.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知